Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
Pembrolizumab with pemetrexed is a promising first-line treatment option for older patients with metastatic nonsquamous NSCLC. This trial was registered at ClinicalTrials.gov (NCT04396457) and the Japan Registry of Clinical Trials (jRCTs041200012).
Authors
- Masashi Kondo (ORCID: https://orcid.org/0000-0001-8818-8316)
- Nobuyuki Yamamoto (ORCID: https://orcid.org/0000-0002-7342-0853)
- Hiroshige Yoshioka (ORCID: https://orcid.org/0000-0001-7724-0481)
- Yoshihito Kogure (ORCID: https://orcid.org/0000-0001-7935-7202)
- Koichi Azuma (ORCID: https://orcid.org/0000-0001-5040-5856)
- Tomoki Kimura (ORCID: https://orcid.org/0000-0001-9745-3329)
- Hiroya Hashimoto (ORCID: https://orcid.org/0000-0003-1865-4953)
- Yasutaka Fukui
- Akihiro Bessho (ORCID: https://orcid.org/0000-0002-0394-7377)
- Naoki Furuya (ORCID: https://orcid.org/0000-0001-7162-5946)
- Haruko Daga (ORCID: https://orcid.org/0000-0002-5191-6233)
- Tadaaki Yamada (ORCID: https://orcid.org/0000-0002-6945-281X)
- Yukihiro Toi (ORCID: https://orcid.org/0000-0001-5983-3531)
- Akiko Moriya Saito (ORCID: https://orcid.org/0000-0003-3723-8445)
- Hideo Saka (ORCID: https://orcid.org/0000-0001-7364-5115)
- Yasushi Fukuda
Institutions
- Kurume University (JP)
- Kansai Medical University (JP)
- Fujita Health University (JP)
- St. Marianna University School of Medicine (JP)
- Wakayama Medical University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Kurashiki Central Hospital (JP)
- Osaka City General Hospital (JP)
- Matsunami General Hospital (JP)
- Okayama Red Cross General Hospital (JP)
- Toyohashi Municipal Hospital (JP)
- Nagoya Medical Center (JP)
- Tosei General Hospital (JP)
- Sendai Kousei Hospital (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100784
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Taiho Pharmaceutical
- Ono Pharmaceutical
- Novartis Pharma
- Chugai Pharmaceutical
- MSD K.K.
- Daiichi Sankyo Europe